Advances in the Treatment of Metastatic Renal Cell Carcinoma

Cancer Treatment and Research
Paulo BergerotSumanta Kumar Pal

Abstract

The treatment landscape for metastatic renal cell carcinoma has constantly been in flux. In 2005, with the advent of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) therapy, the standard of care shifted to agents such as sunitinib and pazopanib. However, more recently there have been datasets, suggesting that next-generation TKIs such as cabozantinib may play an important role in therapy. Furthermore, immunotherapy has had resurgence with the FDA approval of nivolumab with ipilimumab. In the current chapter, we attempt to contextualize available frontline therapies for metastatic renal cell carcinoma with a focus on the CABOSUN and CheckMate 214 clinical trials.

Citations

Apr 30, 2019·Endocrine Connections·Giulia BrescianiTeresa Gagliano
Dec 24, 2019·Cancer Control : Journal of the Moffitt Cancer Center·Fabio CofanoDiego Garbossa
Feb 23, 2019·Integrative Cancer Therapies·Michail NikolaouMaria Tolia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.